C95 COPD ADVANCES IN THERAPY: A Randomized Controlled Trial Of Azd7624, An Inhaled P38 Map Kinase Inhibitor, In COPD Patients On Ics/laba With A History Of Frequent Exacerbations

Naimish.Patel@astrazeneca.com Prior study has shown that p38 MAP kinase (MAPK) is upregulated in alveolar macrophages in patients with COPD, and p38 activation increases with COPD severity. Events of rash and elevated liver enzymes that have been associated with oral p38 inhibitors were in infrequen...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Main Authors: Make, B J, Patel, N, Cunoosamy, D, Brown, M N, Fageras, M, Lundin, S, Asimus, S, Palmer, R, Taib, Z, Jansson, P, Rennard, S I
Format: Article
Language:English
Subjects:
Chronic obstructive pulmonary disease
Kinases
Respiratory therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Naimish.Patel@astrazeneca.com Prior study has shown that p38 MAP kinase (MAPK) is upregulated in alveolar macrophages in patients with COPD, and p38 activation increases with COPD severity. Events of rash and elevated liver enzymes that have been associated with oral p38 inhibitors were in infrequent (
ISSN:1073-449X
1535-4970